par Condorelli, Margherita
;Bruzzone, Marco;Ceppi, Marcello;Ferrari, Alberta;Grinshpun, Albert;Hamy, Anne Sophie;de Azambuja, Evandro
;Carrasco, Estela;Peccatori, Fedro Alessandro;Di Meglio, Antonio;Paluch-Shimon, Shani;Poorvu, Philip P.D.;Venturelli, M;Rousset-Jablonski, Christine;Senechal, Claire;Livraghi, Luca;Ponzone, Riccardo;De Marchis, Laura;Pogoda, Katarzyna;Sonnenblick, Amir;Villarreal-Garza, Cynthia;Cordoba, Octavi;Teixeira, Luis;Clatot, Florian;Punie, Kevin;Graffeo, Rossella;Dieci, Maria V;Pérez-Fidalgo, Jose Alejandro;Duhoux, F P;Puglisi, Fabio;Ferreira, A R;Blondeaux, Eva;Peretz-Yablonski, T;Caron, Olivier;Saule, Claire;Ameye, Lieveke;Balmaña, Judith;Partridge, Ann H;Azim, Hatem A;Demeestere, Isabelle
;Lambertini, Matteo 
Référence ESMO Open, 6, 6, page (100300)
Publication Publié, 2021-12-01




Référence ESMO Open, 6, 6, page (100300)
Publication Publié, 2021-12-01
Article révisé par les pairs
Résumé : | Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2 pathogenic variants. |